Short-term comparative results of segmental resection versus radical resection in two patients with myxofibrosarcoma of the limbs - case series

Sergiu-Andrei Iordache 1 , Bogdan Şerban 1 , 2 , Andreea Vlad 3 , and Adrian Cursaru 1 , 2
  • 1 Orthopedics Department, University Emergency Hospital Bucharest, Romania
  • 2 “Carol Davila” University of Medicine and Pharmacy, , Bucharest, Romania
  • 3 “Grigore Alexandrescu” Children’s Clinical Emergency Hospital Bucharest, , Romania


Introduction: Myxofibrosarcoma is a rare subtype of soft tissue sarcoma with a locally infiltrative behavior and ability to determine distant metastases.

Materials and methods: We presented two myxofibrosarcoma cases who benefited from segmental or radical resection.

Management and outcome: In the case of the 80-year-old woman, with grade 3 myxofibrosarcoma, we practiced radical surgery with scapulohumeral disarticulation followed by adjuvant radiotherapy.

The therapeutic option for the 77-year-old man with grade 2 myxofibrosarcoma was segmental resection followed by adjuvant radiotherapy. After three months, the patient was in a good clinical condition with no sign of local recurrence, but with the presence of pulmonary metastases for the patient who benefited of segmental resection.

Discussion: The radical resection had better short-term results, with no local or distant metastases at three months after surgery, although the tumor had a higher grade (G3), compared to segmental resection practiced for a lower grade tumor (G2), in which case the patient developed pulmonary metastasis at three months follow up.

Conclusion: Myxofibrosarcoma represents a challenging situation regarding the management due to its unpredictive clinical course. Our cases raised the following question: should we consider treating it more aggressively in order to obtain good local control and reduce the risk of metastasis?

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Levy AD, Manning MA, Miettinen MM. Soft-tissue sarcomas of the abdomen and pelvis: Radiologic-Pathologic features, Part 2 - uncommon Sarcomas. Radiographics. 2017 May-Jun; 37(3):797-812.

  • 2. Casali PG, Abecassis N, Bauer S et al. ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1; 29 (Supplement_4):iv51-iv67.

  • 3. Mizuno T, Susa M, Horiuchi K, Shimazaki H, Nakanishi K, Chiba K. Spontaneous Regression of Myxofibrosarcoma of the Thigh after Open Biopsy. Case Rep Oncol. 2019 May 16; 12(2):364-369. doi: 10.1159/000500504. PMID: 31182952. PMCID: PMC6547297.

  • 4. Odei B, Rwigema JC, Eilber FR et al. Predictors of Local Recurrence in Patients with Myxofibrosarcoma. Am J Clin Oncol. 2018; 41(9):827-831. doi:10.1097/COC.0000000000000382.

  • 5. Look Hong NJ, Hornicek FJ, Raskin KA et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013; 20(1):80-86. doi:10.1245/s10434-012-2572-3.

  • 6. Kikuta K, Nakayama R, Yoshida A et al. A histological positive margin after surgery is correlated with high local re-recurrence rate in patients with recurrent myxofibrosarcoma. Jpn J Clin Oncol. 2017; 47(4):334-341. doi:10.1093/jjco/hyw199.

  • 7. Mühlhofer HML, Lenze U, Gersing A et al. Prognostic Factors and Outcomes for Patients with Myxofibrosarcoma: A 13-Year Retrospective Evaluation. Anticancer Res. 2019; 39(6):2985-2992. doi:10.21873/anticanres.13430.

  • 8. Mentzel T, Calonje E, Wadden C et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996; 20(4):391-405. doi: 10.1097/00000478-199604000-00001.

  • 9. Teurneau H, Engellau J, Ghanei I, Vult von Steyern F, Styring E. High Recurrence Rate of Myxofibrosarcoma: The Effect of Radiotherapy Is Not Clear. Sarcoma. 2019; 2019:8517371. doi:10.1155/2019/8517371.

  • 10. Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012; 82(1):361-367. doi:10.1016/j.ijrobp.2010.08.042.


Journal + Issues